NVO logo

NOVO-NORDISK A/S-SPONS ADR

NVONYSE
πŸ† #79 by market capEarnings Feb 3 Β· PostUS Equity
β€”β€”
Quote unavailable
πŸ””
Track NVO
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$167.31B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
6.4%
Slowing
πŸ“ŠGross Margin
80.8%
High
πŸ’΅FCF Margin
13.9%
Healthy
βš–οΈP/S Ratio
3.5x
Fair
Otter Score
72
Strong
No chart data available for NVO.

Trading Snapshot

Day Range
β€”
52-Week Range
$35.12 – $64.16
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
4.42B
Next Earnings
2027-02-03

Fundamentals Snapshot

Annual Revenue
$309.06B
Last Q Revenue
$78.68B
P/E Ratio
10.4
P/S Ratio
3.5x
EPS (TTM)
$25.69
Dividend Yield
4.42%
Dilution (1yr)
βˆ’0.3%
NVO logo

NOVO-NORDISK A/S-SPONS ADR

NVO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$309.1Bβ–² +6.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
81.0%β–Ό βˆ’4.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$127.7Bβ–Ό βˆ’0.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$29.0Bβ–Ό βˆ’58.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
4.45Bβ–Ό βˆ’0.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$104.5Bβ–Ό βˆ’$17.4B YoY
StockOtter Β· stockotter.space

About NOVO-NORDISK A/S-SPONS ADR

Pharma with leading GLP-1 franchise (Ozempic, Wegovy).

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
72/100
Analyst data unavailable.

Latest News & Updates

News unavailable.